ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HLX17

A development code.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Fosun Pharma.

Furthest: phase 3, since Feb 20, 20252 company-led studies, 2 open or runningNext primary completion: Apr 9, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma22 open or runningphase 3since Feb 20, 2025Feb 20, 2025Apr 9, 2027phase 3 · NCT06847334

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 20, 2025First study: phase 3 study in Non-Squamous Non-Small Cell Lung CancerFirst studyNCT06847334 · 772 planned
  2. Aug 22, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07160335 · 174 enrolled · United States, China, Georgia and more

Ahead

  1. Apr 9, 2027Primary completion: phase 3 study in Non-Squamous Non-Small Cell Lung CancerNCT06847334
  2. Apr 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07160335

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07160335Carcinoma, Non-Small-Cell Lung · United States, China, Georgia and more1Active, not recruitingApr 30, 2027174
NCT06847334Non-Squamous Non-Small Cell Lung Cancer3Not yet recruitingApr 9, 2027772

How it is read

Names in the registry

  • “HLX17”, 2 entries

Codes read as this program: HLX17.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.